Travel-associated carbapenem-resistant organisms at a time of increasing geopolitical instability: a UK perspective
File(s)
Published version
Author(s)
Type
Journal Article
Abstract
Background
Conflict and catastrophe compromise multi-national healthcare delivery and present risks for the spread of carbapenem-resistant organisms (CROs). The risk of and ability to detect travel-associated CROs in the UK remain unclear.
Methods
A 10-question survey was sent to microbiology/infection prevention and control (IPC) practitioners of 108 UK acute NHS Trusts/Regions/Boards, exploring recent experience and IPC practices for travel-associated CROs and approaches to extended-spectrum antimicrobial testing. Additionally, major trauma network centres were invited to review detected carbapenemase-producing organism (CPO) molecular data from March 2022 to April 2024, comparing associated travel by the World Health Organization global region using one-way analysis of variance.
Results
Seventy-three surveys were returned. IPC approaches were highly variable, with 19 of 73 (26.0%) centres requiring modification to national screening guidelines. Twenty-four of 73 (32.9%) centres reported CROs associated with recent travel to major conflict areas. Twelve major trauma network centres contributed to review of detected CPOs, finding 297 of 1290 (23.0%) individuals with travel to 52 different countries. In total, 227 of 297 (76.4%) were screening results; 279 of 297 (93.9%) were Enterobacterales. A total of 112 of 297 (37.7%) had travelled to Europe, where carbapenemase diversity was greater than elsewhere (P < 0.001).
Interpretation
A considerable range of UK centres are detecting CROs associated with travel to areas of current major conflict. A more didactic approach to travel history on the first contact with healthcare services is required to stratify CPO risk at admission. These data should be collected prospectively in parallel with projects which successfully embed taking an effective travel history to assess the risk of travel-associated infectious disease. This will allow clearer understanding of travel behaviours and trends, delineate risk and inform effective IPC.
Conflict and catastrophe compromise multi-national healthcare delivery and present risks for the spread of carbapenem-resistant organisms (CROs). The risk of and ability to detect travel-associated CROs in the UK remain unclear.
Methods
A 10-question survey was sent to microbiology/infection prevention and control (IPC) practitioners of 108 UK acute NHS Trusts/Regions/Boards, exploring recent experience and IPC practices for travel-associated CROs and approaches to extended-spectrum antimicrobial testing. Additionally, major trauma network centres were invited to review detected carbapenemase-producing organism (CPO) molecular data from March 2022 to April 2024, comparing associated travel by the World Health Organization global region using one-way analysis of variance.
Results
Seventy-three surveys were returned. IPC approaches were highly variable, with 19 of 73 (26.0%) centres requiring modification to national screening guidelines. Twenty-four of 73 (32.9%) centres reported CROs associated with recent travel to major conflict areas. Twelve major trauma network centres contributed to review of detected CPOs, finding 297 of 1290 (23.0%) individuals with travel to 52 different countries. In total, 227 of 297 (76.4%) were screening results; 279 of 297 (93.9%) were Enterobacterales. A total of 112 of 297 (37.7%) had travelled to Europe, where carbapenemase diversity was greater than elsewhere (P < 0.001).
Interpretation
A considerable range of UK centres are detecting CROs associated with travel to areas of current major conflict. A more didactic approach to travel history on the first contact with healthcare services is required to stratify CPO risk at admission. These data should be collected prospectively in parallel with projects which successfully embed taking an effective travel history to assess the risk of travel-associated infectious disease. This will allow clearer understanding of travel behaviours and trends, delineate risk and inform effective IPC.
Date Issued
2026-03-01
Date Acceptance
2025-11-21
Citation
Journal of Hospital Infection, 2026, 169
ISSN
0195-6701
Publisher
Elsevier BV
Journal / Book Title
Journal of Hospital Infection
Volume
169
Copyright Statement
© 2025 The Author(s). Published by Elsevier Ltd on behalf of The Healthcare Infection Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/41412384
PII: S0195-6701(25)00422-0
Subjects
Antimicrobial resistance
global health security
infection prevention and control
screening
surveillance
Publication Status
Published
Coverage Spatial
England
Date Publish Online
2025-12-16